9.70
+0.23(+2.43%)
Currency In USD
| Previous Close | 9.47 |
| Open | 9.5 |
| Day High | 9.82 |
| Day Low | 9.32 |
| 52-Week High | 11.46 |
| 52-Week Low | 2.22 |
| Volume | 2.34M |
| Average Volume | 1.5M |
| Market Cap | 899.46M |
| PE | -10.66 |
| EPS | -0.91 |
| Moving Average 50 Days | 9.34 |
| Moving Average 200 Days | 5.92 |
| Change | 0.23 |
If you invested $1000 in Rezolute, Inc. (RZLT) 10 years ago, it would be worth $143.7 as of December 04, 2025 at a share price of $9.7. Whereas If you bought $1000 worth of Rezolute, Inc. (RZLT) shares 5 years ago, it would be worth $485 as of December 04, 2025 at a share price of $9.7.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Rezolute to Host Virtual Investor Event on Ersodetug Development Program
GlobeNewswire Inc.
Nov 05, 2025 12:30 PM GMT
Webcast scheduled for Monday, November 10 at 12:00 pm ESTREDWOOD CITY, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused
Rezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Oct 09, 2025 8:05 PM GMT
REDWOOD CITY, Calif., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ: RZLT), (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today announced that it has granted
Rezolute Announces Alignment with FDA on Streamlined Design for Ongoing Phase 3 Trial of Ersodetug in Tumor Hyperinsulinism
GlobeNewswire Inc.
Sep 02, 2025 11:30 AM GMT
Open-label study in as few as 16 tumor hyperinsulinism (HI) patients Study initiated and enrolling patients in the U.S. and Europe Topline data expected in the second half of 2026 REDWOOD CITY, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Rezolute, I